Imperical Blog
SEPTEMBER 7, 2023
Avoiding “Customs Chaos” in Clinical Trials Means Working Closely with Your Importer of Record Many global clinical trial shipments get muddled regarding the critical role and responsibilities of the importer of record (IOR) for clinical trials.
Imperical Blog
SEPTEMBER 7, 2023
Avoiding “Customs Chaos” in Clinical Trials Means Working Closely with Your Importer of Record Many global clinical trial shipments get muddled regarding the critical role and responsibilities of the importer of record (IOR) for clinical trials.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
JANUARY 10, 2021
Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys, together with its partners, has developed and contributed to the development of more than 100 product candidates, of which 27 are currently in clinical development. For more information, please contact: SOURCE: MorphoSys AG via EQS Newswire.
XTalks
APRIL 6, 2023
IRT solutions help clinical trial sponsors meet the complexities of patient randomization and clinical supply management. He also shared how modern software development concepts are impacting IRT platforms and transforming the user experience in clinical trials.
The Pharma Data
JANUARY 24, 2021
Sairiyo is advancing the clinical development of its lead drug candidate, Cepharanthine, a repurposed and reformulated naturally derived compound for the potential treatment of cancer, neurological, inflammatory and infectious diseases. Research and development efforts will be led by Dr. Paul Van Slyke.
Drug Discovery World
MARCH 13, 2023
Drug discovery researchers usually partner with a CDMO to provide support through the development, manufacturing, and clinical supply required to bring a drug to market. CDMOs that integrate digital solutions into their business processes minimise the amount of hands-on work in their operations.
Drug Discovery World
NOVEMBER 3, 2022
The number of therapy classes in development has exploded as research has advanced methods for tackling a vast array of genetic conditions and diseases in both rare disease and common indications. This change in science demands a change in the supply chain to match. 15 years later . References .
Expert insights. Personalized for you.
52 
Let's personalize your content